Dr. Bassel Kisso, MD
Gastroenterology (Gastroenterology Physician)
1505 N Swan Rd Ste 121
Tucson, AZ 85712
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 425
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AZ license 37200
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tucson Medical Center Tucson, AZ
- St Joseph's Hospital Tucson, AZ
- St. Mary's Hospital Tucson, AZ
Medical groups
- Tmc Medical Network (281 clinicians)
- Tucson Physician Group Holdings LLC (201 clinicians)
- Swan Gastroenterology PC (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 425
- Services billed
- 760
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 129 | 128 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 127 | 123 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 106 | 105 |
| Established patient office or other outpatient visit, 30-39 minutes | 85 | 72 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 67 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 64 | 64 |
| Biopsy of large bowel using a flexible endoscope | 40 | 40 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 37 | 37 |
| Destruction of polyp or growth of large bowel using a flexible endoscope | 25 | 25 |
| Diagnostic exam of large bowel using a flexible endoscope | 23 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Famotidine Other prescribers in Tucson, AZ | 183 |
| Omeprazole Other prescribers in Tucson, AZ | 170 |
| Pantoprazole Sodium Other prescribers in Tucson, AZ | 166 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Tucson, AZ | 87 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Tucson, AZ | 42 |
| Linzess (linaclotide) Other prescribers in Tucson, AZ | 39 |
| Sutab (sod sulf/pot chloride/mag sulf) | 29 |
| Dicyclomine Hcl Other prescribers in Tucson, AZ | 23 |
| Suflave (peg 3350/sod sulf,chlr/pot/mag) | 20 |
| Metronidazole Other prescribers in Tucson, AZ | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 111 payments worth $2,433 in total to this clinician.
| AbbVie Inc. | $518 |
|---|---|
| Janssen Biotech, Inc. | $324 |
| Takeda Pharmaceuticals U.S.A., Inc. | $312 |
| Lilly USA, LLC | $218 |
| Genzyme Corporation | $214 |
| Ardelyx, Inc. | $174 |
| Aimmune Therapeutics, Inc. | $150 |
| Mallinckrodt Hospital Products Inc. | $146 |
| Food and Beverage | $2,433 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $60,679 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
Celgene Corporation - A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cenda…
Celgene Corporation - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c. - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028 - Proof of Clinical Principal in Crohn's Disease
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.